Actavis Evolves Through Strategic Business Acquisitions

Actavis made a significant move in 2013 by acquiring Warner Chilcott, a company with a strong portfolio of women's healthcare products. This acquisition added to Actavis's already impressive list of products.

In 2015, Actavis acquired Forest Laboratories, a company with a focus on central nervous system and cardiovascular products. This deal brought in new revenue streams and expanded Actavis's product offerings.

The acquisition of Forest Laboratories was a strategic move by Actavis to diversify its portfolio and increase its presence in the global market. Actavis was able to leverage Forest Laboratories' expertise in these therapeutic areas to drive growth and innovation.

Actavis continued to grow and evolve through strategic business acquisitions, ultimately leading to its merger with Allergan in 2015.

Expand your knowledge: Divi's Laboratories

Desloratadine Actavis has been studied in patients to determine that it is bioequivalent to the reference medicine, Aerius.

The bioequivalence of Desloratadine Actavis to Aerius means that both medicines produce the same levels of the active substance in the body.

Limited studies have been conducted on Desloratadine Actavis in patients, as it is a generic medicine.

The CHMP concluded that Desloratadine Actavis has comparable quality and is bioequivalent to Aerius.

The CHMP recommended that Desloratadine Actavis be given marketing authorisation because the benefit outweighs the identified risk.

This decision was based on EU requirements, which dictate that a generic medicine must be shown to have comparable quality and bioequivalence to the reference medicine.

See what others are reading: Quality Chemical Industries Limited

Desloratadine Actavis has a documented assessment history, which can be found on the European Medicines Agency's website.

The agency has published a report on the procedural steps taken and scientific information after authorisation for Desloratadine Actavis.

This report is available for public viewing and provides valuable insights into the regulatory process.

A variation to the terms of the marketing authorisation for Desloratadine Actavis was also granted, with a scientific conclusion and grounds for the variation documented.

Initial marketing authorisation documents for Desloratadine Actavis are publicly available.

The public assessment report for Desloratadine Actavis is a comprehensive document that outlines the agency's evaluation and decision-making process.

A summary of the CHMP's positive opinion for Desloratadine Actavis is also available, providing a concise overview of the agency's stance on the medication.

Actavis made significant acquisitions that shaped the company's future. In 2013, Actavis acquired Warner Chilcott PLC in a stock-for-stock transaction valued at approximately $8.5 billion.

The combination created a company with approximately $10 billion in anticipated combined annual 2013 revenue. This deal inspired a series of similar moves by other drug companies, but Actavis was exempt from new Treasury Department regulations limiting the ability of companies to perform such inversions.

Actavis continued to expand through acquisitions, including the purchase of Forest Laboratories in 2014 for approximately $25 billion. This acquisition led to a restructuring of the company's executive leadership.

The company's growth continued with the acquisition of Actavis Generics by Teva in 2016 for $40 billion. This deal aimed to create a new Teva with a strong foundation and diversified revenue streams.

Readers also liked: Concord New Energy

The Warner Chilcott Acquisition was a significant deal in the pharmaceutical industry. Actavis acquired Warner Chilcott PLC in a stock-for-stock transaction valued at approximately $8.5 billion on October 1, 2013.

This acquisition created a company with approximately $10 billion in anticipated combined annual 2013 revenue. The combined company was the third-largest US specialty pharmaceutical company.

Actavis relocated its corporate headquarters to Ireland, taking advantage of the lower corporate tax rate of 17% compared to the 35% in the United States. This move was made to "level the playing field" given the high corporate tax rate in the US, according to CEO Paul Bisaro.

The Warner Chilcott Acquisition inspired similar moves by other drug companies, leading to new Treasury Department regulations limiting the ability of companies to perform such inversions.

Consider reading: Teva Nasdaq

In 2014, Actavis made a significant acquisition that would shape the company's future. Actavis acquired Forest Laboratories in a cash and equity transaction valued at approximately $25 billion.

The acquisition was completed on July 1, 2014. This major deal marked a significant milestone for Actavis.

As part of the acquisition, the company restructured its executive leadership. Paul Bisaro was named Executive Chairman, and Brent Saunders was appointed CEO and President of the combined organization.

Teva has completed its acquisition of Actavis Generics in a transaction valued at $40 billion.

The acquisition was originally announced last July, but has suffered delays due to issues receiving clearance from the United States Federal Trade Commission.

Teva's president and CEO, Erez Vigodman, commented on the acquisition, stating that it creates a new Teva with a strong foundation and significantly enhanced financial profile.

The acquisition seeks to unify the strengths of each business to deliver high-quality generic medicines at competitive prices.

As a condition of the European Commission's approval, Teva must divest a standalone business operation based on Actavis' assets, including a portfolio of generic molecules and a manufacturing plant.

The remainder of Allergan's generics will be integrated into Teva's operations, including 33 roles transitioning from Actavis.

Curious to learn more? Check out: Teva Pharmaceuticals